SCHEMBL17972201

SCHEMBL17972201

CC1[C@@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=S

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.57
▸ MTOR P42345 3/20 0.57
▸ THRB P10828 1/20 0.57
▸ MDM2 Q00987 1/20 0.57
▸ NCOA1 Q15788 1/20 0.57
▸ NCOA3 Q9Y6Q9 1/20 0.57
▸ SLC29A1 Q99808 2/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ CYP2C19 P33261 3/20 0.42
▸ THPO P40225 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ PMP22 Q01453 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ GMNN O75496 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16576362 1.00 LMNA (0.57) LMNAMTORTHRBMDM2NCOA1
SCHEMBL4455737 1.00 LMNA (0.57) LMNAMTORTHRBMDM2NCOA1
SCHEMBL6302404 0.88 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL30664789 0.88 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL288517 0.88 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL42103 0.88 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20953418 0.87 LMNA (0.70) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20953417 0.87 LMNA (0.70) LMNAMTORTHRBMDM2NCOA1
Water SCHEMBL6475042 0.87 LMNA (0.70) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16946221 0.87 LMNA (0.70) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections EMORY UNIVERSITY (US) 2024-01-02 — — US disclosed
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections EMORY UNIVERSITY (US) 2024-01-02 — — US disclosed
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO DEFENSE THREAT REDUCTION AGENCY, US DOD 2016-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220595-A1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, NTPCR, TYMP LMNA 2417/4885MTOR 2992/4885THRB 3403/4885
US-11857560-B2 Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections SLC28A1, PNP, SLC28A2 LMNA 1285/4885MTOR 1701/4885THRB 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback